Siremadlin Succinate

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H24Cl2N6O4.C4H6O4
Molecular Weight	673.501
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.COC1=NC=C(C2=NC3=C([C@@H](N(C3=O)C4=CC(Cl)=CN(C)C4=O)C5=CC=C(Cl)C=C5)N2C(C)C)C(OC)=N1

InChI

InChIKey=WOEIHDWLQDGIAG-BDQAORGHSA-N

InChI=1S/C26H24Cl2N6O4.C4H6O4/c1-13(2)33-21-19(30-22(33)17-11-29-26(38-5)31-23(17)37-4)25(36)34(18-10-16(28)12-32(3)24(18)35)20(21)14-6-8-15(27)9-7-14;5-3(6)1-2-4(7)8/h6-13,20H,1-5H3;1-2H2,(H,5,6)(H,7,8)/t20-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C26H24Cl2N6O4
Molecular Weight	555.413
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tumour suppressor p53/oncoprotein Mdm2 6 Target ID: CHEMBL1907611 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27542305 \| https://patents.google.com/patent/WO2015084804A1/en	Inhibitor 8504		0.13 nM [IC50]

C_max

Value	Dose	Analyte	Population
118 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
121 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg 1 times / 3 weeks multiple, oral dose: 12.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
100 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
126 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg 1 times / 3 weeks multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
467 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
499.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg 1 times / 3 weeks multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
663.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
778.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg 1 times / 3 weeks multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1168.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1309.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2258.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1533.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg 1 times / 3 weeks multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2015.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2601.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg 1 times / 3 weeks multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3750.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3199.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg 1 times / 3 weeks multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1039.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
856.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / week multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
851.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / 3 weeks multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1444.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1136.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg 1 times / week multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1430.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg 1 times / 3 weeks multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2051.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1160 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / week multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1421.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1483.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1359.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg 1 times / 3 weeks multiple, oral dose: 12.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1773.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1879.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg 1 times / 3 weeks multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8028.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7178.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg 1 times / 3 weeks multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14287 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11675.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg 1 times / 3 weeks multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26255.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20070.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
55102.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22887 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg 1 times / 3 weeks multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
41422.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37768.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg 1 times / 3 weeks multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
81662.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
48124.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg 1 times / 3 weeks multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18481.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5270 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / week multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11864.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / 3 weeks multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23727.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6323.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg 1 times / week multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17921 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg 1 times / 3 weeks multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19303 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4886.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / week multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14701.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
7.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	12.5 mg 1 times / 3 weeks multiple, oral dose: 12.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
31.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
22.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	25 mg 1 times / 3 weeks multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	50 mg 1 times / 3 weeks multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	100 mg 1 times / 3 weeks multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg 1 times / 3 weeks multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	350 mg 1 times / 3 weeks multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
40.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	400 mg 1 times / 3 weeks multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / week multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	120 mg 1 times / 3 weeks multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	150 mg 1 times / 3 weeks multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34862243/	200 mg 1 times / 3 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SIREMADLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.	2016-10-01	27542305

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:30:55 GMT 2025` Edited by `admin` on `Mon Mar 31 22:30:55 GMT 2025`
Record UNII	0XPX99P4ZT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HDM-201 SUCCINATE

Preferred Name

English

Siremadlin Succinate

Official Name

English

HDM201 SUCCINATE

Code

English

HDM201 BBA

Code

English

NVP-HDM201-BBA

Code

English

Butanedioic acid, compd. with (6S)-5-(5-chloro-1,2-dihydro-1-methyl-2-oxo-3-pyridinyl)-6-(4-chlorophenyl)-2-(2,4-dimethoxy-5-pyrimidinyl)-5,6-dihydro-1-(1-methylethyl)pyrrolo[3,4-d]imidazol-4(1H)-one (1:1)

Systematic Name

English

SIREMADLIN SUCCINATE [USAN]

Common Name

English

(6S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one succinate

Systematic Name

English

Code System Code Type Description

FDA UNII

0XPX99P4ZT